The epidemiological profile of cervical cancer suggests strongly that this is a sexually transmitted disease and that the aetiological agent is a genital pathogen. At one time or another almost every sexually transmitted pathogen has been implicated as the oncogen (often without any substantial evidence), but at the present time the genital papillomaviruses (HPVs) are the favoured candidates' and their claim is supported by two principal lines of evidence. The first is the demonstration that 80-90% (using Southern blotting) of invasive cancers of the cervix contain HPV DNA sequences of the other so-called oncogenic types, predominantly HPV 16 (which is present in about 50% of lesions) HPV 18 or 31, 33,  35.`'5 Viral sequences are present in the malignant cells; these sequences are transcribed and viral proteins are expressed.67 Cervical intra-epithelial lesions also contain HPV DNA with the oncogenic types occurring in high frequency in high grade CIN's.89 The evidence that these viral DNAs may be more than passengers comes from in vitro studies which show that HPV 16 or HPV 18 DNA when transfected into normal human genital keratinocytes can immortalise or transform these cells,'1-4 a phenomenon observed hitherto in keratinocytes only with the experimental DNA tumour virus SV 40.
There is however no clear epidemiological evidence supporting an aetiological role for HPV in cervical cancer and this relates in part to our ignorance of the natural history of HPVs and the difficulties encountered in determining the prevalence of HPV infection. These viruses cannot be grown in tissue culture, and thus the identity of authentic viral antigens is uncertain, prohibiting both serological classification and the use of serology in epidemiological studies. There are several possible explanations for these wide disparities. PCR is vulnerable to accidental contamination and high numbers of false positives are a hazard when using this technique.3' The design of the detection primer sets has differed in different studies and this may be important. The incorporation of anti-contamination primers into the assays has been shown to reduce the number of false positives significantly2729 bringing the rates for detection found by PCR to the same range as those determined by hybridisation. Anti-contamination primers`are mixtures of primers of the common HPVs 6, 11, 16, 18, 33 with the oligonucleotide sequences designed to flank the plasmid cloning sites to prevent amplification of contaminating cloned HPV types. In the best PCR studies which have been reported concensus primers, those located in the highly conserved regions of the HPV genome, L1 and E1 are used to detect HPV DNA sequences. Type specific PCR is then used to type the HPVs in these samples and it is here that anti-contamination primers are so useful in eliminating or reducing contamination from cloned HPV used in that laboratory. Of course any lab using concensus primers to do large scale epidemiological studies may then run the risk of contamination from novel HPV DNA amplified from one sample round in the next set of samples and contamination primers cannot be designed unless the sequence of the contaminating DNA is known. This is a possible explanation for the rather high detection rate by PCR of novel uncharacterised HPVs. Those studies which reported high prevalence of HPV 16 DNA and did not use anticontamination primers should be re-evaluated. The prevalence of infection with HPV 16 and other HPV types may be, of course, genuinely different in different geographic locations, in differing social classes and in different age groups all of which would be of crucial importance in determining the role of HPV infection in cervical neoplasia. However, this cannot be evaluated until reliable data are available on the prevalence of HPV, and in particular HPV 16 
